Bethany Dean | Meet the Speakers: Med-Tech Expo 2026

Key Takeaways

• Borderline products blur lines between device, cosmetic, and drug categories
• Regulatory misclassification can trigger costly enforcement actions
• Real‑world case studies illustrate correct classification pathways
• Marketing teams gain guidance on permissible product claims

Pulse Analysis

The regulatory environment for health‑related products is becoming increasingly complex as technology blurs the lines between traditional categories. In the United States, the FDA’s 510(k) pathway, de novo classification, and the Center for Devices and Radiological Health intersect with the agency’s oversight of cosmetics and drugs, while the European Union’s MDR and IVDR impose parallel criteria. Companies developing hybrid solutions—such as wearable sensors with therapeutic claims or cosmetic‑grade skin‑care devices—must decipher which framework applies, or risk costly re‑work and delayed launches.

Misclassification is more than a paperwork issue; it can trigger warning letters, mandatory recalls, or civil penalties that erode profit margins and investor confidence. Real‑world examples, like a smart moisturizer marketed as a skin‑tightening device, illustrate how a seemingly benign claim can reclassify a product as a medical device, invoking stricter pre‑market approval requirements. Conversely, over‑regulating a true cosmetic can inflate development costs and stifle innovation. Understanding the nuanced triggers—intended use, mode of action, and performance claims—is essential for compliance teams to chart the correct regulatory pathway early in product development.

Bethany Dean’s session at Med‑Tech Expo 2026 offers a timely deep dive into these challenges. Drawing on Taylored Consultancy’s experience guiding firms through FDA and EU submissions, she will equip attendees with a decision‑tree approach to assess product classification, showcase case studies that avoided enforcement, and provide marketing playbooks that align messaging with regulatory limits. For executives, R&D leaders, and brand managers, the insights promise faster market access, reduced legal exposure, and a clearer roadmap for bringing innovative health solutions to consumers worldwide.